Neoadjuvant chemotherapy with or without the concurrent hormone therapy that has downregulated estrogen level in estrogen receptor positive breast cancer: NACED randomized multicenter phase II trial.

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG07): The efficacy and its correlation with circulating endothelial cells.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.618 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 618-618

Author(s):

T. Ueno ◽

N. Masuda ◽

S. Kamigaki ◽

T. Morimoto ◽

S. Nakamura ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Estrogen Receptor ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Trial ◽

Circulating Endothelial Cells ◽

Multicenter Phase ◽

Abstract P4-02-05: A Phase II Trial of Fulvestrant and RAD001 (Everolimus) in Patients with Metastatic Estrogen Receptor Positive Breast Cancer after Aromatase Inhibitor Failure; a Study in Progress

10.1158/0008-5472.sabcs10-p4-02-05 ◽

2010 ◽

Cited By ~ 3

Author(s):

F Badin ◽

E Romond ◽

M Chambers ◽

B Shelton ◽

S Birk ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Aromatase Inhibitor ◽

Phase Ii ◽

Phase Ii Trial ◽

Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: A randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy

The Breast ◽

10.1016/j.breast.2013.03.002 ◽

2013 ◽

Vol 22 (3) ◽

pp. 263-267 ◽

Cited By ~ 11

Author(s):

Takashi Hojo ◽

Takayuki Kinoshita ◽

Shigeru Imoto ◽

Chikako Shimizu ◽

Hirotsugu Isaka ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Endocrine Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii ◽

Optimal Duration ◽

Post Menopausal ◽

The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

OncoImmunology ◽

10.1080/2162402x.2016.1219008 ◽

2016 ◽

Vol 5 (11) ◽

pp. e1219008 ◽

Cited By ~ 27

Author(s):

Yusuke Tomita ◽

Min-Jung Lee ◽

Sunmin Lee ◽

Saori Tomita ◽

Saranya Chumsri ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Trial ◽

Epigenetic Therapy ◽

Correlative Analysis ◽

Locally Recurrent ◽

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells

Cancer Medicine ◽

10.1002/cam4.1516 ◽

2018 ◽

Vol 7 (6) ◽

pp. 2442-2451 ◽

Cited By ~ 5

Author(s):

Takayuki Ueno ◽

Norikazu Masuda ◽

Shunji Kamigaki ◽

Takashi Morimoto ◽

Futoshi Akiyama ◽

...

Keyword(s):

Breast Cancer ◽

Endothelial Cells ◽

Estrogen Receptor ◽

Low Dose ◽

Phase Ii Trial ◽

Circulating Endothelial Cells ◽

Clinical Implications ◽

Multicenter Phase ◽

Abstract OT2-01-03: Phase II Trial of the addition of pembrolizumab to letrozole and palbociclib in patients with metastatic estrogen receptor positive breast cancer who have stable disease on letrozole and palbociclib

10.1158/1538-7445.sabcs16-ot2-01-03 ◽

2017 ◽

Cited By ~ 1

Author(s):

Y Yuan ◽

P Frankel ◽

T Synold ◽

S Yost ◽

P Lee ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Stable Disease ◽

Phase Ii Trial ◽

Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy

Cancer Letters ◽

10.1016/j.canlet.2012.04.017 ◽

2012 ◽

Vol 324 (1) ◽

pp. 42-47 ◽

Cited By ~ 6

Author(s):

Ryo Tsunashima ◽

Yasuto Naoi ◽

Kazuki Kishi ◽

Yosuke Baba ◽

Atsushi Shimomura ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

High Risk ◽

Neoadjuvant Chemotherapy ◽

Response To Neoadjuvant Chemotherapy ◽

Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor–Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial

Journal of Nuclear Medicine ◽

10.2967/jnumed.117.194654 ◽

2017 ◽

Vol 59 (2) ◽

pp. 197-203 ◽

Cited By ~ 12

Author(s):

Michel Paquette ◽

Éric Lavallée ◽

Serge Phoenix ◽

René Ouellet ◽

Helena Senta ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Estrogen Receptor ◽

Cancer Patients ◽

Phase Ii ◽

The Novel ◽

Breast Cancer Patients ◽

Ongoing Phase ◽

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study

Cancer Medicine ◽

10.1002/cam4.2423 ◽

2019 ◽

Vol 8 (12) ◽

pp. 5468-5481

Author(s):

Nobuaki Sato ◽

Norikazu Masuda ◽

Takashi Morimoto ◽

Takayuki Ueno ◽

Chizuko Kanbayashi ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Open Label ◽

Open Label Phase ◽

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer

Frontiers in Oncology ◽

10.3389/fonc.2013.00317 ◽

2013 ◽

Vol 3 ◽

Cited By ~ 2

Author(s):

David M. Marcus ◽

Jeffrey M. Switchenko ◽

Roshan Prabhu ◽

Ruth O’Regan ◽

Amelia Zelnak ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Chemotherapy ◽

Hormonal Therapy ◽

Neoadjuvant Hormonal Therapy ◽

Menopausal Women ◽

Post Menopausal ◽